SequelSEC

Structure Therapeutics Inc. GPCR

Pharmaceutical Preparations · CIK 0001888886 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$176.56M
Fiscal year ended 2025-12-31
Free cash flow
-$225.81M
Fiscal year ended 2025-12-31

Structure Therapeutics Inc. (GPCR) reported net income of -$141.20M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Structure Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Structure Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$176.56M-$158.23M-$102.78M-$52.56M
Net income-$141.20M-$122.53M-$89.62M-$51.32M
Research & development$225.26M$108.81M$70.10M$36.19M
Weighted-average diluted sharesshares 177.60Mshares 157.92Mshares 110.20Mshares 9.58M
Pretax income-$140.69M-$122.22M-$89.38M-$51.30M
Income tax expense$515.00K$310.00K$236.00K$17.00K
Diluted EPS$-0.80$-0.78$-0.81$-5.51
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$61.55M$49.41M$32.67M$16.37M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Structure Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$799.62M$169.51M$129.79M$26.09M
Total assets$1.58B$903.33M$482.02M$97.84M
Current assets$1.57B$891.21M$473.61M$93.09M
Total liabilities$67.54M$38.49M$29.05M$13.01M
Current liabilities$63.28M$36.02M$24.74M$13.01M
Total equity incl. NCI$1.52B$864.84M$452.97M-$115.14M
Temporary (mezzanine) equityUnavailableUnavailable$0$199.98M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$13.86M$8.02M$4.74M$6.01M

Cash flow

Structure Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$222.20M-$116.64M-$79.49M-$46.12M
Capital expenditures$3.61M$1.29M$2.17M$155.00K
Investing cash flow$89.80M-$358.91M-$268.34M-$62.11M
Financing cash flow$762.52M$515.26M$451.53M$29.01M
Net change in cash$630.11M$39.72M$103.70M-$79.21M
Stock-based compensation$28.99M$18.79M$8.19M$2.51M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Structure Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$225.81M-$117.93M-$81.66M-$46.28M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio24.81x24.74x19.14x7.16x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GPCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.